Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2013-10-18 Director's Dealing
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2013-10-18 English
PRIMARY DOCUMENT
Director's Dealing
2013-10-18 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it is a Regulation FD Disclosure, specifically furnishing a press release dated October 17, 2013. The document explicitly states that the information is being furnished and not filed, and it includes no financial statements or substantive financial data. The length is only 2932 characters, which is short and consistent with an announcement rather than a full report. There is no indication of quarterly or annual financial results, audit information, or management discussion. Therefore, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2013-10-17 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce unscheduled material events or corporate changes. The text indicates it is a Regulation FD Disclosure with an attached press release. The document is short (2940 characters) and primarily furnishes a press release rather than containing detailed financial data or a full report. It explicitly states the press release is being furnished and not filed, and the document does not contain financial statements or substantive financial analysis. Therefore, this is a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into other specific categories like Annual Report or Earnings Release.
2013-10-10 English
PRIMARY DOCUMENT
Director's Dealing
2013-10-09 English
PRIMARY DOCUMENT
Director's Dealing
2013-10-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.